Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID... see more

TSXV:CLAS.H - Post Discussion

Claritas Pharmaceuticals Inc > To be honest I can't disagree with this posting
View:
Post by Dude51 on Sep 10, 2020 4:44pm

To be honest I can't disagree with this posting

Development of R-107 for CILI funded under contract with BARDA

The development of R-107 for the treatment of CILI has been funded in whole or in part with federal funds under contract No. HHSO100201600016C from the Biomedical Advanced Research and Development Authority (BARDA). BARDA is a division of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services. In 2016, BARDA awarded Salzman Group a $15.9-million (U.S.) contract to develop R-107 as a treatment for CILI as part of continuing preparedness efforts to protect the nation from potential health security threats. An additional $69.9-million (U.S.) could be released to Salzman Group over the next 36 months, as developmental milestones are achieved. The results of the murine study presented above were obtained in 2016 prior to BARDA funding.

Barda liked them enough to give them 15.9 Million dollars. What part are you bashers not understanding?

Comment by Scotty on Sep 10, 2020 5:21pm
Alright I tap out. KLY's the best. Good luck.
Comment by Moonshiner592 on Sep 10, 2020 6:53pm
That's the spirit Scotty! 
Comment by Scotty on Sep 10, 2020 7:55pm
Yep, I don't have the proper education to communicate with that level of autism.
Comment by JMark80 on Sep 10, 2020 8:08pm
You really have no idea, and for an old fart that's depressing!
Comment by Matteo1234 on Sep 11, 2020 3:06am
They certainly have skin in the game. Thanks for the heads up on the Barda Grant. Can you imagine if they get traction? Pappy goes BOOM!!!!!!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities